GENERAL NANOTHERAPEUTICS, LLC
Nanoparticles targeted to immunoregulatory cells for expansion and functional activity to treat autoimmune diseases
- Sector
- Biotech
- Total capital
- $300K
- Federal grants
- $300K
- 1 award · 2022
- Rank in peer group#8 of 392
- Private capital raised
- None on recordNo Form D filings on SEC EDGAR. Some raises are not filed.
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 0
- 2 pending
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase I · Nanoimmunotherapy for chronic immune-mediated diseases$300K
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 392 peers
Line = medianBiotech · Molecule
- Federal grants#8 · top 2%
- Linked publications#8 · top 2%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
No founders are linked to this company yet.
Founders appear once a person is matched to the company through its own patents, grants or filings. We never infer people from social profiles.
Checked: USPTO inventors; federal award principal investigators; SEC Form D related persons · Oct 23, 2026
Claim this profile to add your teamWhat it has protected
USPTO · 0 granted of 2- PendingMethods And Compositions For Treatment Of Immune-mediated DiseasesUSPTOApplication 18254690
- PendingMethods And Composition For Treatment Of Immune-mediated DiseasesUSPTOApplication PCTUS2021060612
Recent research by its founders
- CD2-targeted nanoparticles encapsulating IL-2 induce tolerogenic Tregs and TGF-β-producing NK cells that stabilize Tregs for long-term therapeutic efficacy in immune-mediated disorders20253 cites
- CD2 targeted nanoparticles containing IL-2 mimic fetal-maternal tolerance of pregnancy by inducing synergistic TGF-β-producing NK cells and Tregs20251 cites
- Nanoparticles loaded with IL-2 and TGF-β promote transplantation tolerance to alloantigen202410 cites
Related companies, and why
- SHASQI, INC.Similar federal contract value in Biotech · null in contracts
- PRIMITY BIO, INC.Similar federal contract value in Biotech · null in contracts
- Mountain Valley MD Holdings Inc.Similar federal contract value in Biotech · null in contracts
- Wildflower Biopharma IncSimilar federal contract value in Biotech · null in contracts
- Island Pharmaceuticals LtdSimilar federal contract value in Biotech · null in contracts
- LactaLogics, Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .